drugset / Trial / NCT02760602
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's disease (AD).
Timeline
- Start
- 2016-06
- Primary completion
- 2017-05
- Completion
- 2017-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Solanezumab | Protein / enzyme biologic | — | Intravenous |